Suppr超能文献

替奈普酶溶栓治疗时代前、大脑中动脉闭塞患者的溶栓后结局。

Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era.

机构信息

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

出版信息

J Stroke Cerebrovasc Dis. 2013 Aug;22(6):805-10. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.009. Epub 2012 Jun 19.

Abstract

This study examined outcomes of patients with acute ischemic stroke (AIS) with major cerebral artery occlusion after the approval of intravenous recombinant tissue-type plasminogen activator (IV rt-PA) but before approval of the MERCI retriever. We retrospectively enrolled 1170 consecutive patients with AIS and major cerebral artery occlusion (496 women; mean age, 73.9 ± 12.3 years) who were admitted within 24 hours after the onset of symptoms to 12 Japanese stroke centers between October 2005 and June 2009. Cardioembolism was a leading cause of AIS in this group (68.2%). The occlusion sites of the major cerebral arteries included the common carotid artery and internal carotid artery (ICA; 29.6%), middle cerebral artery (52.2%), and basilar artery (7.6%). Recanalization therapy (RT) was performed in 32.0% of patients (IV rt-PA, 20.0%; neuroendovascular therapy, 9.4%; combined, 2.5%). Symptomatic intracerebral hemorrhage within 36 hours with a ≥ 1-point increase in the National Institutes of Health Stroke Scale score occurred in 5.3% of the patients. At 3 months (or at hospital discharge), 29.3% of the patients had a favorable outcome (based on a modified Rankin scale score of 0-2), 23.8% were bedridden, and 15.6% died. After multivariate adjustment, RT was positively associated with a favorable outcome and negatively associated with death, whereas age, baseline National Institutes of Health Stroke Scale score, and ICA occlusion were negatively associated with a favorable outcome and positively associated with death. One-third of the patients with AIS and major cerebral artery occlusion were treated with RT, which was independently associated with favorable outcomes and death. However, 40% of the patients became bedridden or died during the post-alteplase, pre-MERCI era in Japan.

摘要

这项研究调查了在批准静脉注射重组组织型纤溶酶原激活剂(IV rt-PA)但在批准 MERCI 取栓器之前,患有急性缺血性脑卒中(AIS)伴大脑主要动脉闭塞的患者的结局。我们回顾性纳入了 2005 年 10 月至 2009 年 6 月期间,12 家日本卒中中心收治的 1170 例发病 24 小时内的 AIS 伴大脑主要动脉闭塞患者(496 例女性,平均年龄 73.9 ± 12.3 岁)。心源性栓塞是该组 AIS 的主要病因(68.2%)。主要大脑动脉闭塞部位包括颈总动脉和颈内动脉(29.6%)、大脑中动脉(52.2%)和基底动脉(7.6%)。32.0%的患者接受了血管再通治疗(RT)(IV rt-PA,20.0%;神经血管内治疗,9.4%;联合治疗,2.5%)。36 小时内出现症状性颅内出血,NIHSS 评分增加≥1 分的患者占 5.3%。3 个月时(或出院时),29.3%的患者预后良好(改良 Rankin 量表评分 0-2),23.8%卧床不起,15.6%死亡。多变量调整后,RT 与良好结局呈正相关,与死亡呈负相关,而年龄、基线 NIHSS 评分和颈内动脉闭塞与良好结局呈负相关,与死亡呈正相关。三分之一的 AIS 伴大脑主要动脉闭塞患者接受了 RT 治疗,与良好结局和死亡独立相关。然而,在日本,接受阿替普酶治疗后、MERCI 取栓器治疗前的这一时期,40%的患者卧床不起或死亡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验